C-8M5WGlyscend
gut-targeted polymers, dynamic barrier, metabolic surgery mimicry
modulatingdevice hardware
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-8M5W
C-8M5WC-8M5Wgut-targeted polymers, dynamic barrier, metabolic surgery mimicry
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Glyscend gut-targeted polymers, dynamic barrier, metabolic surgery mimicry
Glyscend is developing a novel class of oral, gut-targeted polymer therapies for type 2 diabetes, obesity, and metabolic disease. Its dynamic barrier approach seeks to provide benefits associated with gastric bypass surgery and duodenal exclusion devices without invasive surgery or procedures. The company describes its drugs as polymer therapeutic platform-based candidates that non-invasively mimic the physiology of bariatric surgery.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Glyscend — Translational · Lower middle. Derived deterministically from 5 extracted project(s). Most-advanced status: phase 2. Band: translational. Modifiers: +5 depth (2 programs at…
Source: Deterministic